61Y Stock Overview A pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Marinus Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Marinus Pharmaceuticals Historical stock prices Current Share Price US$0.51 52 Week High US$9.85 52 Week Low US$0.22 Beta 1.03 1 Month Change 88.43% 3 Month Change -66.33% 1 Year Change -94.87% 3 Year Change -94.90% 5 Year Change -93.59% Change since IPO -98.76%
Recent News & Updates
Immedica Pharma AB entered into an agreement to acquire Marinus Pharmaceuticals, Inc. (NasdaqGM:MRNS) for $31 million. Jan 01
Forecast to breakeven in 2027 Jan 01 Immedica Pharma AB entered into an agreement to acquire Marinus Pharmaceuticals, Inc. (NasdaqGM:MRNS) for $31 million. Dec 31
Marinus Pharmaceuticals Receives Nasdaq Bid Price Deficiency Notice Dec 11
Third quarter 2024 earnings released: US$0.42 loss per share (vs US$0.61 loss in 3Q 2023) Nov 14
New minor risk - Profitability Oct 25 See more updates
Immedica Pharma AB entered into an agreement to acquire Marinus Pharmaceuticals, Inc. (NasdaqGM:MRNS) for $31 million. Jan 01
Forecast to breakeven in 2027 Jan 01 Immedica Pharma AB entered into an agreement to acquire Marinus Pharmaceuticals, Inc. (NasdaqGM:MRNS) for $31 million. Dec 31
Marinus Pharmaceuticals Receives Nasdaq Bid Price Deficiency Notice Dec 11
Third quarter 2024 earnings released: US$0.42 loss per share (vs US$0.61 loss in 3Q 2023) Nov 14
New minor risk - Profitability Oct 25
Marinus Pharmaceuticals Announces Topline Results from Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives Oct 25
New major risk - Financial position Oct 03
Forecast to breakeven in 2026 Oct 03
New major risk - Financial position Sep 02
Second quarter 2024 earnings released: US$0.63 loss per share (vs US$0.61 loss in 2Q 2023) Aug 14
Marinus Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Year 2024 Aug 14
Marinus Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024 Jul 30
Marinus Pharmaceuticals Announces Ganaxolone Approves in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder Jul 19 Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell Small Cap Completeness Index
Marinus Pharmaceuticals Announces Topline Results from Phase 3 Rise Trial of IV Ganaxolone in Refractory Status Epilepticus Jun 18
Robbins LLP Files A Class Action Against Marinus Pharmaceuticals, Inc Jun 09
Robbins LLP Files A Class Action Against Marinus Pharmaceuticals, Inc Jun 08
Marinus Pharmaceuticals, Inc. Announces Key Business Updates for Tuberous Sclerosis Complex Program May 18
New minor risk - Profitability May 10
Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024 May 09
First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.67 loss in 1Q 2023) May 08
Marinus Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
New major risk - Share price stability Apr 17
New minor risk - Market cap size Apr 16
Marinus Pharmaceuticals, Inc. Provides Update on the Phase 3 RAISE Trial Apr 15
Marinus Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024 Apr 05
Full year 2023 earnings released: US$2.63 loss per share (vs US$0.51 loss in FY 2022) Mar 07
Marinus Pharmaceuticals, Inc. Provides Earnings Guidance for 2024 Mar 06
Marinus Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024 Feb 21
Marinus Pharmaceuticals, Inc. Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results from the Second Generation Formulation MAD Study Nov 21
Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023 Nov 09 Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023
Third quarter 2023 earnings released: US$0.61 loss per share (vs US$1.93 profit in 3Q 2022) Nov 08
New major risk - Revenue and earnings growth Nov 08
Marinus Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 25
Second quarter 2023 earnings released: US$0.61 loss per share (vs US$1.06 loss in 2Q 2022) Aug 11
Marinus Pharmaceuticals, Inc. Announces European Commission Approval of ZTALMY (Ganaxolone) Oral Suspension for Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder in Patients Two to 17 Years of Age Aug 01
Marinus Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jul 29
New major risk - Share price stability Jun 13
Marinus Pharmaceuticals, Inc. Receives Positive CHMP Opinion for ZTALMY®? (ganaxolone) for the Adjunctive Treatment of Seizures Associated with CDKL5 Deficiency Disorder May 27 Marinus Pharmaceuticals, Inc. Appoints Sarah Noonberg as Member of the Board May 18
First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.53 loss in 1Q 2022) May 12
Full year 2022 earnings released: US$0.51 loss per share (vs US$2.69 loss in FY 2021) Mar 09
Marinus Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 07, 2023 Feb 14 Marinus Pharmaceuticals, Inc. Appoints Steve Pfanstiel as Chief Operating Officer
Marinus Pharmaceuticals, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 Jan 06
Marinus Pharmaceuticals, Inc. Announces Board Changes Nov 18 Marinus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $59.9979 million. Nov 10
Third quarter 2022 earnings released: EPS: US$1.93 (vs US$0.53 loss in 3Q 2021) Nov 09 Marinus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $59.9979 million. Nov 08
Marinus Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.65 loss in 2Q 2021) Aug 13
Marinus Pharmaceuticals, Inc. Provides Revenue Guidance for the Fiscal Year 2022 Aug 12
Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY (Ganaxolone) for Seizures Associated with CDKL5 Deficiency Disorder Jul 29
Marinus Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Jul 14
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2000 Dynamic Index Jun 26
Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus Jun 09
First quarter 2022 earnings released: US$0.53 loss per share (vs US$0.74 loss in 1Q 2021) May 14 Marinus Pharmaceuticals, Inc. Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus May 06
Marinus Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022 Apr 21
Marinus Pharmaceuticals, Inc. Announces Publication in the Lancet Neurology of Ztalmy® (Ganaxolone) Phase 3 Marigold Trial Results Apr 15 Marinus Pharmaceuticals, Inc. announced that it has received $1.230085 million in funding Apr 05
Marinus Pharmaceuticals, Inc. announced that it has received $30 million in funding from Oaktree Capital Management, L.P. Apr 01
Marinus Pharmaceuticals, Inc. Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials Feb 24
Marinus Pharmaceuticals, Inc. Announces New Clinical and Research Data to Be Presented At American Epilepsy Society Meeting Dec 05
Marinus Pharmaceuticals, Inc. Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder Sep 21
European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency Disorder Aug 28
Marinus Pharmaceuticals, Inc. Announces Topline Data from Open-Label Phase 2 Trial Evaluating Safety and Efficacy of Adjunctive Oral Ganaxolone Treatment in 23 Patients with Seizures Associated with Tuberous Sclerosis Complex Aug 18
Marinus Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline Update Aug 05
Independent Director Enrique Carrazana has left the company Jul 13
Forecast to breakeven in 2024 May 18
Marinus Pharmaceuticals Provides an Update on its Clinical and Regulatory Development Activities May 18
Marinus Pharmaceuticals, Inc. Announces Executive Changes, Effective April 12, 2021 Mar 11
Revenue beats expectations Mar 10
New 90-day high: €13.30 Mar 03
Marinus Pharmaceuticals, Inc. Unveils New Brand as the Company Prepares for Commercialization Feb 24
Marinus Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 09, 2021 Feb 11 Marinus Pharmaceuticals, Inc. Announces Agreement with Ceribell, Inc
Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application for the Use of Ganaxolone in CDKL5 Deficiency Disorder Jan 14
New 90-day low: €10.26 Dec 24
Marinus Pharmaceuticals, Inc. Appoints Christy Shafer as Chief Commercial Officer Nov 10 Shareholder Returns 61Y DE Pharmaceuticals DE Market 7D 39.5% 2.2% 1.7% 1Y -94.9% -15.0% 9.4%
See full shareholder returns
Return vs Market: 61Y underperformed the German Market which returned 9.6% over the past year.
Price Volatility Is 61Y's price volatile compared to industry and market? 61Y volatility 61Y Average Weekly Movement 30.7% Pharmaceuticals Industry Average Movement 5.6% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 61Y's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 61Y's weekly volatility has increased from 21% to 31% over the past year.
About the Company Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential.
Show more Marinus Pharmaceuticals, Inc. Fundamentals Summary How do Marinus Pharmaceuticals's earnings and revenue compare to its market cap? 61Y fundamental statistics Market cap €28.52m Earnings (TTM ) -€136.19m Revenue (TTM ) €30.50m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 61Y income statement (TTM ) Revenue US$31.47m Cost of Revenue US$102.78m Gross Profit -US$71.31m Other Expenses US$69.18m Earnings -US$140.49m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.55 Gross Margin -226.64% Net Profit Margin -446.49% Debt/Equity Ratio -141.4%
How did 61Y perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/08 10:46 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Marinus Pharmaceuticals, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Skorney Baird François Brisebois Craig-Hallum Capital Group LLC Douglas Tsao H.C. Wainwright & Co.
Show 12 more analysts 
